跳至主要内容
临床试验/NCT02492386
NCT02492386Unknown2 期

Safety and Feasibility of Bioabsorbable Everolimus-Eluting Stents for Patients With Internal Pudendal Artery-Related Arteriogenic Erectile Dysfunction (PERFECT-ABSORB)

National Taiwan University Hospital0 个研究点目标入组 15 人开始时间: 2015年7月最近更新:
适应症

试验速览

阶段
2 期
入组人数
15
主要终点
CT angiographic binary restenosis

研究概览

简要总结

In this prospective, unblinded, single-arm, single-center study, investigators would like to assess the feasibility and safety of the bioabsorbable everolimus-eluting stents in patients with erectile dysfunction and concomitant internal pudendal artery stenoses. A total of 15 bioabsorbable vascular scaffolds (BVSs) are planned to be assessed and will be deployed in the internal pudendal artery, with a 1:1 ratio of both proximal and distal segments.

详细描述

Background: Obstructive pelvic arterial lesions were present in approximately 70-80% of patients aged >50 years and having erectile dysfunction. Previous studies have shown that most arterial stenoses were present in the internal pudendal and common penile artery segments. Investigators have also demonstrated that angioplasty for both internal pudendal and penile arteries is safe and can achieve clinically significant improvement in erectile function in ~60% of patients with erectile dysfunction. Nevertheless, in the ZEN study and investigators' preliminary observation, the 6-month angiographic binary restenosis rate for drug-eluting stents (DES) in internal pudendal artery approached 30-50%. The internal pudendal artery requires integral vasomotor function to provide sufficient blood supply during erection, whereas metallic stents impair vasomotor function. A fully bioabsorbable drug-eluting stent that scaffolds the vessel wall when needed and then disappear once the acute recoil and constrictive remodeling processes have subsided is therefore particularly advantageous for the internal pudendal artery. Investigators herein would like to assess the feasibility and safety of the bioabsorbable everolimus-eluting stents in patients with erectile dysfunction and concomitant internal pudendal artery stenoses.

Methods: This prospective, unblinded, single-arm, single-center study is a feasibility trial designed to provide preliminary observations and generate hypotheses for future studies. A total of 15 BVSs are planned to be assessed and will be deployed in the internal pudendal artery, with a 1:1 ratio of both proximal and distal segments. All subjects will undergo pelvic CT angiography at baseline and 6 months after intervention. Invasive selective pudendal angiography will be performed 6-9 months after intervention as well. Intravascular ultrasound and/or optical coherence tomography (OCT) imaging will be obtained during invasive angiography. The primary feasibility endpoint is CT angiographic binary restenosis (≥50% lumen diameter stenosis) at 6 months.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • men 20 years of age or older with "consistent" erectile dysfunction defined as both IIEF-5 scores, taken at least 4 weeks apart, are in the range of 5 to 21 points and with a difference of ≤2 points;
  • the anatomical inclusion criteria, based on pelvic CT angiography, are unilateral luminal diameter stenosis ≥70% or bilateral diameter stenoses ≥50% in the internal pudendal arteries with reference vessel diameter ≥2.5 mm and ≤4.0 mm and a target-lesion length ≤30 mm.

排除标准

  • the arterial inflow to the penis is entirely from the accessory pudendal arteries rather than the usual internal pudendal artery and common penile artery;
  • the presence of focal diameter stenosis ≥70% in the common penile artery, internal iliac artery, or anterior division of inferior gluteal artery;
  • previous radical prostatectomy, pelvic radiation, or Peyronie's disease;
  • untreated hypogonadism (serum total testosterone <300 ng/dL within 14 days before enrollment);
  • acute coronary syndrome, stroke, or life-threatening arrhythmia within 3 months before enrollment;
  • poorly controlled diabetes mellitus with glycosylated hemoglobin levels >9%;
  • serum creatinine levels >2.5 mg/dL;
  • bleeding diathesis or known hypercoagulopathy;
  • life expectancy of fewer than 12 months;
  • known intolerance to contrast agents.

结局指标

主要结局

CT angiographic binary restenosis

时间窗: 6 months

Binary restenosis is defined as \>=50% lumen diameter stenosis

次要结局

  • Diameter measured by invasive angiography(6-9 months)
  • Diameter stenosis measured by invasive angiography(6-9 months)
  • Late loss measured by invasive angiography(6-9 months)
  • International Index of Erectile Function (IIEF)-5 score(1, 3, 6, and 12 months)
  • Major adverse events(1, 3, 6, and 12 months)

研究者

申办方类型
Other
责任方
Sponsor

相似试验

Unknown
2 期
Single Arm Study of RAD001 as Monotherapy in Treatment in Advanced CholangiocarcinomaCholangiocarcinoma
NCT01525719Ratchavithi Hospital40
Unknown
4 期
Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After Kidney Transplantation in AdultsKidney TransplantImmunosuppression
NCT01455649Deise de Boni Monteiro de Carvalho30
已完成
不适用
Evaluation of Outcomes of EES Implantation for Unprotected Left Main Coronary Artery Stenosis (PRE-COMBAT 2)Coronary Artery Disease
NCT01348022Seung-Jung Park397
已完成
2 期
Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II StudyPoorly Differentiated Malignant Neuroendocrine CarcinomaNeuroendocrine Carcinoma, Grade 3Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3Neuroendocrine Tumor, Grade 3 and Disease Progression as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)
NCT02113800AIO-Studien-gGmbH40
终止
2 期
Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine TumorsGastrointestinal TumorsPancreatic TumorsGastrointestinal Neuroendocrine TumorsPancreatic Neuroendocrine Tumors
NCT01648465Hellenic Cooperative Oncology Group25